|
Lilly stomach cancer drug prolongs life
in colon cancer study
Send a link to a friend
[September 13, 2014]
By Ransdell Pierson
(Reuters) - Eli Lilly and Co's LLY.N Cyramza stomach-cancer drug
prolonged survival of patients with advanced colon cancer in a
late-stage study, the U.S. drugmaker said on Friday.
|
|
 Based on favorable data from the Phase III study, Lilly said it
would ask regulators in the first half of 2015 to approve Cyramza in
patients with colorectal cancer that has spread to other parts of
the body. It plans to present detailed results from the trial at a
scientific meeting next year.
The 1,000-patient global study, called RAISE, involved patients who
had previously failed to adequately benefit from Roche Holding AG's
ROG.VX Avastin and other standard treatments.
Patients taking Cyramza along with chemotherapy showed a statistical
improvement in survival, compared with those in the study who took a
placebo and chemotherapy.
Cyramza, like Avastin, blocks a protein called VEGF that tumors
create and use to form blood vessels that provide them nourishment.
The U.S. Food and Drug Administration in April approved Cyramza for
treatment of advanced stomach cancer. Cowen and Co expects the drug
to garner annual sales of $1.2 billion by 2020 as a treatment of
multiple types of cancer.
In a research note on Friday, JPMorgan analyst Chris Schott said he
expected Cyramza sales to reach $1.35 billion in 2020, mostly from
use against stomach cancer, but also from "modest" sales for lung
cancer and a "limited contribution" from second-line treatment of
colorectal cancer.
[to top of second column] |
Colorectal cancer is the world's fourth leading cause of cancer
deaths, having killed nearly 700,000 people in 2012, Lilly said.
Shares of the Indianapolis-based company edged up 1 cent to $65.19
in morning trading on the New York Stock Exchange.
(Additional reporting by Ankur Banerjee in Bangalore; Editing by
Lisa Von Ahn)
[© 2014 Thomson Reuters. All rights
reserved.] Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
